Painful Total Knee Replacement (TKA) and I-one Therapy

Multicenter Prospective Observational Study in Patients With Painful Total Knee Replacement and I-one Therapy

Arthroplasty operations are very frequent and their number is constantly increasing. The success of prosthetic surgery is linked to surgical factors (prosthesis type, prosthesis design, prosthesis material, surgical hand) and 'biological' factors (inflammation, pain, oedema, impingement). It is well known that important functional limitations may result mainly from an overreaction involving the peri-articular tissues. This is particularly true after total knee arthroplasty (TKA) surgery, during which a large part of the bone tissue and part of the peri-articular tissues (joint capsule, ligaments, synovium) are dislodged or removed. In the days following arthroplasty operations, the presence of a strong local inflammatory component is associated with pain and functional limitation, which usually resolves within a few months; however, it can sometimes take longer, and sometimes result in a chronic, albeit modest, inflammatory condition that lasts for years. There is still a percentage of 11-25% of patients who remain not completely satisfied with the result achieved with prosthetic surgery . Baker et al. state that 19.8% of patients experience pain one year after arthroplasty . Beswick et al. report that many patients (10-34%) continue to experience significant pain and functional limitation after arthroplasty even years later.

Study Overview

• Status: Recruiting
• Conditions: Knee Pain Swelling
• Intervention / Treatment: Device: I-ONE

Detailed Description

The inflammatory response is mainly due to the presence of pro-inflammatory cytokines in the synovium; in fact, it has been shown that there is an inverse relationship between the amount of the pro-inflammatory cytokine IL-6 in the joint in patients undergoing TKA and the patient's functional recovery one month after surgery. It has also been shown that a high concentration in synovial fluid of catabolic factors, such as TNF-α, MMP-13 and IL-6, is predictive of a lower resolution of pain 2 years after prosthesis surgery. Sellam and Berenbaum emphasise the importance of considering the synovial membrane as a promising target for new therapeutic strategies to control inflammation and thus prevent joint problems or resolve clinical symptoms . There is an increasing need to find a local anti-inflammatory treatment to be implemented in the immediate post-surgery period to avoid chronic pain. Not only the pain condition, but also the functional condition, although better than the starting condition, cannot be considered completely satisfactory; 37% of patients one year after surgery have not achieved a complete functional recovery.

Extensive translational research has shown that biophysical stimulation with I-ONE® therapy (Pulsed Electromagnetic Field by IGEA SpA, Carpi, Italy) is able to modulate cartilage metabolism by increasing the reduction of the release of inflammation mediators involved in cartilage degeneration, such as inflammatory cytokines (IL-6 and IL-8) and lipid mediators of inflammation (prostaglandins E2), enhances the anti-inflammatory effect of individual adenosine agonists A2A and A3 by increasing the release of the anti-inflammatory cytokine IL-10.

In the clinic, I-ONE® therapy is able to prevent and/or slow down the degenerative phenomena that accompany surgery in patients with cartilage lesions treated with microfractures under arthroscopy in the knee or ankle, both in patients undergoing autologous chondrocyte transplantation in the presence of scaffolds at the knee , and in patients with osteochondral lesions of the talus, treated by graft transplantation, with addition of bone marrow concentrate. I-ONE® therapy has also proven effective in patients undergoing total knee replacement with or without patella prosthesis and after reverse shoulder replacement surgery.

Postoperative noninvasive therapy with the use of PEMF in patients with painful TKA resulted in significant improvement in pain and functional recovery, as demonstrated by the preliminary results of this prospective cohort study.

The study plans to recruit patients with painful TKA whose pain occurred from at least 30 days after surgery to a maximum of 180 days after surgery. All patients will be instructed to use local non invasive biophysical therapy with I-ONE® therapy (1.5 mT, 75 Hz) for 4 hours a day for 60 days. Clinical evaluations such as Visual Analog Score (VAS), SF-12 Health Survey (SF-12), EuroQol (EQ-5D) are scheduled at 1 month, 2, 6, 12 and 24 months after PEMF treatment; Knee Society Score (KSS) is scheduled at 3 months of follow-up. The use of nonsteroidal anti-inflammatory drugs (NSAIDs) is also recorded. Patients will be analyzed into three different groups based on the time elapsed between surgery and the beginning of PEMF therapy: Group 1 (30-90 days), Group 2 (91-150 days) and Group 3 (151-180 days).

• Study Type: Observational
• Enrollment (Estimated): 237

Contacts and Locations

• Study Contact: Name: Leo Massari, MD; Phone Number: +390532239797; Email: msl@unife.it

Study Locations

• Italy
  • Bari, Italy
    • Recruiting
    • Policlinico di Bari
    • Contact: Biagio Moretti
  • Roma, Italy
    • Recruiting
    • Ospedale Santo Spirito in Sassia/Ospedale San Filippo Neri Roma
    • Contact: Francesco Falez
  • BO
    • Bologna, BO, Italy
      • Recruiting
      • IRCCS Istituto Ortopedico Rizzoli
      • Contact: Francesco Traina
  • BS
    • Brescia, BS, Italy
      • Recruiting
      • Poliambulanza Brescia
      • Contact: Francesco Benazzo
  • PV
    • Pavia, PV, Italy
      • Recruiting
      • Policlinico San Matteo Pavia
      • Contact: Mario Mosconi
  • TO
    • Torino, TO, Italy
      • Recruiting
      • Ospedale Mauriziano Torino
      • Contact: Roberto Rossi
  • VR
    • Negrar, VR, Italy
      • Recruiting
      • Ospedale Sacro Cuore Don Calabria Negrar Verona
      • Contact: Claudio Zorzi

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

outpatients, orthopaedic clinic

Description

Inclusion Criteria:

• informed consent
• painful total knee replacement at least 30 ± 3 days post-op up to a maximum of 180 ± 3 days post-op
• VAS ≥ 5
• absence of infection

Exclusion Criteria:

• pain caused by mechanical problems (misalignment, mobilisation, etc.),
• the presence of hip prostheses,
• previous knee infections,
• rheumatoid arthritis
• autoimmune diseases
• systemic diseases
• tumours
• major axial deviations
• obesity (BMI > 30 kg/m2).

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Painfull TKA; Pulsed electromagnetic field therapy	Device: I-ONE; Pulsed Electromagnetic fields joint therapy

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evaluate pain resolution after treatment with I-ONE® therapy in patients with painful TKA at least 1 month after surgery.	Visual analogue scales (VAS, 0 is the minimum and 10 is maximum values) are psychometric measuring instruments designed to document the characteristics of disease-related symptom severity in individual patients and use this to achieve a rapid classification of symptom severity and disease control.	baseline, 30 days, 60 days, 180 days, 1 year, 2 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
reduced NSAID intake	NSAID usage registration	baseline, 30 days, 60 days, 180 days, 1 year, 2 years
improved recovery of joint function	The SF-12 (12-Item Short Form Surveyis range from 0 to 100) a self-reported outcome measure assessing the impact of health on an individual's everyday life. It is often used as a quality of life measure.	baseline, 30 days, 60 days, 180 days, 1 year, 2 years

Collaborators and Investigators

• Sponsor: University Hospital of Ferrara
• Investigators: Principal Investigator: Leo Massari, MD, Azienda Ospedaliera-Universitaria Arcispedale S. Anna di Ferrara

Study record dates

Study Major Dates

• Study Start (Actual): October 22, 2020
• Primary Completion (Estimated): October 21, 2025
• Study Completion (Estimated): October 21, 2025

Study Registration Dates

• First Submitted: March 19, 2024
• First Submitted That Met QC Criteria: March 19, 2024
• First Posted (Actual): March 26, 2024

Study Record Updates

• Last Update Posted (Actual): March 28, 2024
• Last Update Submitted That Met QC Criteria: March 26, 2024
• Last Verified: March 1, 2024

More Information

Terms related to this study

• Other Study ID Numbers: 483/2020/Disp/AOUFe

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No